DFE Pharma has achieved ISO 22301 certification for Business Continuity Management Systems (BCMS) at its head office in Goch, Germany.

The certification supports the company’s strategy to ensure secure and consistent supply of pharmaceutical excipients, even under disruptive conditions.

ISO 22301 is an internationally recognized standard focused on business continuity, requiring organizations to demonstrate robust planning and resilience. The certification follows an independent, third-party audit of DFE Pharma’s systems, evaluating its ability to maintain operations and deliver products during unexpected events.

According to the company, the certification confirms that critical business functions and infrastructure at the Goch site are prepared to continue operating in the face of potential disruptions. This includes processes designed to reduce recovery time, limit downtime, and enhance crisis response capabilities.

“For over 125 years, DFE Pharma has been committed to delivering premium-quality excipients and expert solutions through a reliable supply chain,” said Sven Abend, CEO at DFE Pharma.

“In light of increasing global uncertainties, ensuring business continuity has become more crucial than ever. Our achievement of ISO 22301 certification underscores our proactive and enduring commitment to Business Continuity Management.”

DFE Pharma’s approach includes a long-term investment in developing its BCMS to manage supply chain risk and meet the expectations of pharmaceutical and nutraceutical partners worldwide. The company believes this certification offers customers assurance that it can mitigate risks and prevent supply disruptions.